Integrating viral hepatitis management into the emergency department: A further step towards viral hepatitis elimination.

Cost-effectiveness analysis Emergency service HBV HCV HDV Mass screening

Journal

JHEP reports : innovation in hepatology
ISSN: 2589-5559
Titre abrégé: JHEP Rep
Pays: Netherlands
ID NLM: 101761237

Informations de publication

Date de publication:
Jan 2024
Historique:
received: 19 06 2023
revised: 26 09 2023
accepted: 27 09 2023
medline: 11 12 2023
pubmed: 11 12 2023
entrez: 11 12 2023
Statut: epublish

Résumé

Many people with HCV and HBV infection are unaware of their condition, particularly at-risk and vulnerable populations who face barriers for screening and linkage to care. Emergency departments are often their only point of contact with the health system. This is a prospective study investigating HBsAg and HCV antibody testing, with reflex testing for HDV antibodies and HCV RNA, in adults attending an emergency department and requiring a blood test. Positive cases were linked to care. A cost-effectiveness analysis was performed. From February 2020 to February 2022, a total of 17,560 individuals were screened. HBsAg was detected in 91 (0.5%), HCV RNA in 128 (0.7%), and HDV antibodies in two (0.01%) individuals. Nearly 40% of positive cases were unaware of their condition. Linkage to care was achieved in 42 of 56 HBsAg-positive and 45 of 69 HCV RNA-positive participants who were candidates for referral. HCV and HBV screening On emergency department screening for hepatitis B, C, and D in Barcelona, the prevalence of HBsAg was 0.5% and HCV RNA 0.7%, approximately threefold higher than that observed in the general population. This strategy diagnosed patients with active HCV infection and no risk factors, who would not have been screened according to the current recommendations. Screening and linkage to care of viral hepatitis is cost-effective in this setting. We evaluated the performance and cost-effectiveness of a viral hepatitis screening programme implemented in an emergency department, which aimed to identify and link to care people living with hepatitis B and C. Our findings reveal a threefold higher prevalence of hepatitis B and C than in the general Spanish population, possibly attributable to the role of the emergency department as the main healthcare gateway for vulnerable populations, who have a higher prevalence of viral hepatitis. Risk factors for viral hepatitis could not be identified in most people living with hepatitis B and C attending the emergency department; hence, screening beyond risk factors should be considered in hepatitis detection strategies. Emergency department screening is cost-effective for hepatitis C and is a cost-saving strategy for hepatitis B in our setting. These data should inform future updates to clinical guidelines.

Sections du résumé

Background & Aims UNASSIGNED
Many people with HCV and HBV infection are unaware of their condition, particularly at-risk and vulnerable populations who face barriers for screening and linkage to care. Emergency departments are often their only point of contact with the health system.
Methods UNASSIGNED
This is a prospective study investigating HBsAg and HCV antibody testing, with reflex testing for HDV antibodies and HCV RNA, in adults attending an emergency department and requiring a blood test. Positive cases were linked to care. A cost-effectiveness analysis was performed.
Results UNASSIGNED
From February 2020 to February 2022, a total of 17,560 individuals were screened. HBsAg was detected in 91 (0.5%), HCV RNA in 128 (0.7%), and HDV antibodies in two (0.01%) individuals. Nearly 40% of positive cases were unaware of their condition. Linkage to care was achieved in 42 of 56 HBsAg-positive and 45 of 69 HCV RNA-positive participants who were candidates for referral. HCV and HBV screening
Conclusions UNASSIGNED
On emergency department screening for hepatitis B, C, and D in Barcelona, the prevalence of HBsAg was 0.5% and HCV RNA 0.7%, approximately threefold higher than that observed in the general population. This strategy diagnosed patients with active HCV infection and no risk factors, who would not have been screened according to the current recommendations. Screening and linkage to care of viral hepatitis is cost-effective in this setting.
Impact and implications UNASSIGNED
We evaluated the performance and cost-effectiveness of a viral hepatitis screening programme implemented in an emergency department, which aimed to identify and link to care people living with hepatitis B and C. Our findings reveal a threefold higher prevalence of hepatitis B and C than in the general Spanish population, possibly attributable to the role of the emergency department as the main healthcare gateway for vulnerable populations, who have a higher prevalence of viral hepatitis. Risk factors for viral hepatitis could not be identified in most people living with hepatitis B and C attending the emergency department; hence, screening beyond risk factors should be considered in hepatitis detection strategies. Emergency department screening is cost-effective for hepatitis C and is a cost-saving strategy for hepatitis B in our setting. These data should inform future updates to clinical guidelines.

Identifiants

pubmed: 38074506
doi: 10.1016/j.jhepr.2023.100932
pii: S2589-5559(23)00263-X
pmc: PMC10698271
doi:

Types de publication

Journal Article

Langues

eng

Pagination

100932

Informations de copyright

© 2023 The Authors.

Déclaration de conflit d'intérêts

JL has served as a speaker for Gilead and Pfizer. JCR has served as a speaker for and has received travel grants from Gilead. RDH is an employee of Pharmacoeconomics & Outcomes Research Iberia, a consultancy firm that has received unconditional funding from Gilead Sciences. FRF is a consultant, advisor, and speaker for Gilead. MAC is an employee of Pharmacoeconomics & Outcomes Research Iberia, a consultancy firm that has received unconditional funding from Gilead Sciences. MRB has received research educational and travel grants from Gilead and has served as a speaker for Gilead and GSK. RE has served as a speaker and advisor for Gilead and Abbvie. MB has served as a speaker and advisor for Gilead and Abbvie. All other authors declare no competing interests. Please refer to the accompanying ICMJE disclosure forms for further details.

Références

Eur J Gastroenterol Hepatol. 2018 Sep;30(9):1077-1081
pubmed: 29939868
Hepatology. 2012 Jun;55(6):1652-61
pubmed: 22213025
Liver Int. 2021 Mar;41(3):456-463
pubmed: 33389788
Health Econ. 2018 Apr;27(4):746-761
pubmed: 29282798
Eur J Health Econ. 2010 Oct;11(5):513-20
pubmed: 20405159
Lancet Glob Health. 2022 Feb;10(2):e278-e287
pubmed: 35063115
Lancet Gastroenterol Hepatol. 2019 Feb;4(2):135-184
pubmed: 30647010
J Hepatol. 2017 Aug;67(2):370-398
pubmed: 28427875
PLoS One. 2016 Mar 11;11(3):e0150546
pubmed: 26967517
Rev Esp Enferm Dig. 2017 Dec;109(12):809-817
pubmed: 29152988
J Hepatol. 2023 Aug;79(2):576-580
pubmed: 37030400
Lancet. 2015 Oct 17;386(10003):1546-55
pubmed: 26231459
Gastroenterol Hepatol. 2017 Aug - Sep;40(7):433-446
pubmed: 28645446
Liver Int. 2023 Jan;43(1):60-68
pubmed: 36050826
Clin Infect Dis. 2017 Jun 01;64(11):1540-1546
pubmed: 28207069
Value Health. 2020 Aug;23(8):1003-1011
pubmed: 32828211
J Hepatol. 2006 Oct;45(4):529-38
pubmed: 16879891
Aliment Pharmacol Ther. 2020 Jan;51(1):158-166
pubmed: 31721254
PLoS One. 2021 Dec 20;16(12):e0260608
pubmed: 34928962
J Hepatol. 2023 Nov 27;:
pubmed: 38030035
J Viral Hepat. 2022 Jul;29(7):559-568
pubmed: 35357750
PLOS Glob Public Health. 2023 Feb 23;3(2):e0001559
pubmed: 36963042

Auteurs

Jordi Llaneras (J)

Emergency Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain.

Juan Carlos Ruiz-Cobo (JC)

Liver Unit, Hospital Universitari Vall d'Hebron, Barcelona, Spain.

Ariadna Rando-Segura (A)

Microbiology Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
CIBEREHD, Instituto de Salud Carlos III, Madrid, Spain.

Ana Barreira-Díaz (A)

Liver Unit, Hospital Universitari Vall d'Hebron, Barcelona, Spain.

Raquel Domínguez-Hernández (R)

Pharmacoeconomics & Outcomes Research Iberia (PORIB), Madrid, Spain.

Francisco Rodríguez-Frías (F)

CIBEREHD, Instituto de Salud Carlos III, Madrid, Spain.
Biochemistry Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain.

Magda Campins (M)

Epidemiology Service, Hospital Universitari Vall d'Hebron, Barcelona, Spain.

Joan Colom (J)

Public Health Agency of Catalonia, Health Department, General Subdirection on Prevention, Control and Care on Addictions, HIV, STI and Viral Hepatitis, Barcelona, Spain.

Miguel Angel Casado (MA)

CIBEREHD, Instituto de Salud Carlos III, Madrid, Spain.
Pharmacoeconomics & Outcomes Research Iberia (PORIB), Madrid, Spain.

Albert Blanco-Grau (A)

Biochemistry Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain.

Juan Bañares (J)

Liver Unit, Hospital Universitari Vall d'Hebron, Barcelona, Spain.

Arnau Monforte (A)

Infectious Diseases Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain.

Anna Falcó-Roget (A)

Infectious Diseases Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain.

Lourdes Ruíz (L)

Liver Unit, Hospital Universitari Vall d'Hebron, Barcelona, Spain.

Beatriz Meza (B)

Emergency Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain.

Tomàs Pumarola (T)

Microbiology Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain.

Mar Riveiro-Barciela (M)

Liver Unit, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
CIBEREHD, Instituto de Salud Carlos III, Madrid, Spain.

Rafael Esteban (R)

Liver Unit, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
CIBEREHD, Instituto de Salud Carlos III, Madrid, Spain.

María Buti (M)

Liver Unit, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
CIBEREHD, Instituto de Salud Carlos III, Madrid, Spain.

Classifications MeSH